Review Article
Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients
Z.Z.N. Yiu,
C.E.M. Griffiths,
R.B. Warren,
Corresponding Author
Z.Z.N. Yiu
The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD U.K
Correspondence
Zenas Yiu.
E-mail: [email protected]
Search for more papers by this authorC.E.M. Griffiths
The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD U.K
Search for more papers by this authorR.B. Warren
The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD U.K
Search for more papers by this authorZ.Z.N. Yiu,
C.E.M. Griffiths,
R.B. Warren,
Corresponding Author
Z.Z.N. Yiu
The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD U.K
Correspondence
Zenas Yiu.
E-mail: [email protected]
Search for more papers by this authorC.E.M. Griffiths
The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD U.K
Search for more papers by this authorR.B. Warren
The Dermatology Centre, Salford Royal NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, M6 8HD U.K
Search for more papers by this authorFunding sources None.
Conflicts of interest C.E.M.G. has received honoraria and/or research grants from Abbvie, Actelion, Amgen, Celgene, Lilly, GSK-Stiefel, Janssen, MSD, Novartis, Pfizer and Sandoz. R.B.W. has acted as a consultant and/or speaker and/or received research grants for Abbvie, Amgen, Celgene, Eli Lilly, Pfizer, Novartis and Janssen, all of whom manufacture biological therapies. Z.Z.N.Y: none declared.
Summary
The effects of biological therapies for psoriasis on pregnancy outcomes and lactation, and male fertility and mutagenicity are common concerns in the clinical setting. There is relatively little evidence to guide the clinician and patient. Here, we review the safety profile of the commonly used biological therapies for psoriasis in individuals of reproductive potential. Safety data were derived from large-scale registries, adverse event reporting databases, clinical trials and case reports. We assessed the effect of each therapy on adverse pregnancy outcomes including congenital malformations, and lactation with maternal administration, and male fertility and potential mutagenicity with paternal administration. We provide applicable guidance to inform clinician and patient before and after conception.
References
- 1Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228–33.
- 2Vasiliauskas EA, Church JA, Silverman N et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006; 4: 1255–8.
- 3Zelinkova Z, de Haar C, de Ridder L et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053–8.
- 4 AbbVie Inc. Prescribing information for adalimumab, 2013. Available at: http://www.rxabbvie.com/pdf/humira.pdf (last accessed 18 July 2014).
- 5Murashima A, Watanabe N, Ozawa N et al. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum. Ann Rheum Dis 2009; 68: 1793–4.
- 6Berthelsen BG, Fjeldsoe-Nielsen H, Nielsen C, Hellmuth E. Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding. Rheumatology 2010; 49: 2225–7.
- 7 Janssen. Medicines information – Remicade®, 2013. Available at: http://www.remicade.com/shared/product/remicade/prescribing-information.pdf (last accessed 18 July 2014).
- 8 Amgen. Enbrel®, Prescribing information, 2012. Available at: http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf (last accessed 18 July 2014).
- 9Roux CH, Brocq O, Breuil V et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF) therapy. Rheumatology 2007; 46: 695–8.
- 10Berthelot JM, De Bandt M, Goupille P et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. Joint Bone Spine 2009; 76: 28–34.
- 11Chambers CD, Johnson DL, Jones KL. Pregnancy outcome in women exposed to anti-TNF-alpha medications: the OTIS rheumatoid arthritis in pregnancy study. Arthritis Rheum 2004; 50: S479.
- 12Carter JD, Ladhani A, Ricca LR et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009; 36: 635–41.
- 13Winger EE, Reed JL. Was risk properly assessed in Carter et al’s safety assessment of tumor necrosis factor antagonists during pregnancy? J Rheumatol 2009; 36: 2122.
- 14Crijns HJ, Jentink J, Garne E et al. The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population. J Rheumatol 2011; 38: 1871–4.
- 15Casanova MJ, Chaparro M, Domènech E et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433–40.
- 16Verstappen SMM, King Y, Watson KD et al. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 823–6.
- 17Katz JA, Antoni C, Keenan GF. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385–92.
- 18Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012; 107: 1409–22.
- 19Vesga L, Terdiman JP, Mahadevan U. Adalimumab use in pregnancy Gut 2005; 54: 890–4.
- 20Mishkin DS, Van Deinse W, Becker JM et al. Successful use of adalimumab (Humira) for Crohn's disease in pregnancy. Inflamm Bowel Dis 2006; 12: 827–8.
- 21Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig Dis Sci 2006; 51: 2045–7.
- 22Jurgens M, Brand S, Filik L et al. Safety of adalimumab in Crohn's disease during pregnancy: case report and review of the literature. Inflamm Bowel Dis 2010; 16: 1634–5.
- 23Dessinioti C, Stefanaki I, Stratigos AJ et al. Pregnancy during adalimumab use for psoriasis. J Eur Acad Dermatol Venereol 2010; 25: 734–46.
- 24Cheent K, Nolan J, Shariq S et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010; 4: 603–5.
- 25Reich K, Griffiths C, Barker J et al. Recommendations for the long-term treatment of psoriasis with infliximab: a dermatology expert group consensus. Dermatology 2008; 217: 268–75.
- 26Zelinkova Z, van der Ent C, Bruin KF et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol 2013; 11: 318–21.
- 27Martin PL, Sachs C, Imai N et al. Development in the cynomolgus macaque following administration of ustekinumab, a human anti-IL-12/23p40 monoclonal antibody, during pregnancy and lactation. Birth Defects Res B Dev Reprod Toxicol 2010; 89: 351–63.
- 28Lebwohl M, Leonardi C, Griffiths CEM et al. Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. J Am Acad Dermatol 2012; 66: 731–41.
- 29Andrulonis R, Ferris LK. Treatment of severe psoriasis with ustekinumab during pregnancy. J Drugs Dermatol 2012; 11: 1241.
- 30Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Spontaneous abortion during ustekinumab therapy. J Dermatol Case Rep 2012; 4: 105–7.
- 31Ali YM, Kuriya B, Orozco C et al. Can tumor necrosis factor inhibitors be safely used in pregnancy? J Rheumatol 2010; 37: 9–17.
- 32Mahadevan U, Cucchiara S, Hyams JS et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214–23.
- 33Ben-Horin S, Yavzori M, Kopylov U et al. Detection of infliximab in breast milk of nursing mothers with inflammatory bowel disease. J Crohns Colitis 2011; 5: 555–8.
- 34Kane S, Ford J, Cohen R et al. Absence of infliximab in infants and breast milk from nursing mothers receiving therapy for Crohn's disease before and after delivery. J Clin Gastroenterol 2009; 43: 613–16.
- 35Stengel JZ, Arnold HL. Is infliximab safe to use while breastfeeding. World J Gastroenterol 2008; 14: 3085–7.
- 36Fritzsche J, Pilch A, Mury D et al. Infliximab and adalimumab use during breastfeeding. J Clin Gastroenterol 2012; 46: 718–19.
- 37Marits P, Landucci L, Sundin U et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 2014; 8: 881–9.
- 38Koren G. Therapeutic drug monitoring principles in the neonate. Clin Chem 1997; 43: 222–7.
- 39Ostensen M, Eigenmann GO. Etanercept in breast milk. J Rheumatol 2004; 31: 1017–18.
- 40Keeling S, Wolbink G. Measuring multiple etanercept levels in the breast milk of a nursing mother with rheumatoid arthritis. J Rheumatol 2010; 37: 7.
- 41Suominen JS, Wang Y, Kaipia A. Tumor necrosis factor-alpha (TNF-alpha) promotes cell survival during spermatogenesis, and this effect can be blocked by infliximab, a TNF-alpha antagonist. Eur J Endocrinol 2004; 151: 629–40.
- 42Said TM, Agarwal A, Falcone T et al. Infliximab may reverse the toxic effects induced by tumor necrosis factor alpha in human spermatozoa: an in vitro model. Fertil Steril 2005; 83: 1665–73.
- 43Mahadevan U, Terdiman JP, Aron J et al. Infliximab and semen quality in men with inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 395–9.
- 44Wildi LM, Haraoui B. Reversible male infertility under treatment with an anti-TNFα agent: a case report. Ann Rheum Dis 2012; 71: 473–4.
- 45Villiger PM, Caliezi G, Cottin V et al. Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 2010; 69: 1842–4.
- 46Rezvani A, Ozaras N. Infertility improved by etanercept in ankylosing spondylitis. Indian J Pharmacol 2008; 40: 276–7.
- 47Saougou I, Markatseli TE, Papagoras C et al. Fertility in male patients with seronegative spondyloarthropathies treated with infliximab. Joint Bone Spine 2013; 80: 34–7.
- 48Paschou S, Voulgari PV, Vrabie IG et al. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 2009; 36: 351–4.
- 49Puchner R, Danninger K, Puchner A et al. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 2012; 30: 765–7.
- 50 Janssen. Stelara® information, 2013. Available at: http://www.stelarainfo.com/hcp/assets/pdf/PrescribingInformation.pdf (last accessed 18 July 2014).
- 51Clowse M, Wolf DC, Stach C et al. Outcomes of pregnancy in subjects exposed to certolizumab pegol. Arthritis Rheum 2012; 64: S702 (abstr. 1643).
- 52Burden AD, Warren RB, Kleyn CE et al. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 2012; 166: 545–54.
